{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T03:31:48Z","timestamp":1784604708123,"version":"3.55.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"am","delay-in-days":391,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["brachyjournal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brachytherapy"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.brachy.2023.03.004","type":"journal-article","created":{"date-parts":[[2023,5,6]],"date-time":"2023-05-06T01:04:09Z","timestamp":1683335049000},"page":"531-541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["The impact of brachytherapy boost for anal canal cancers in the era of de-escalation treatments"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9138-7604","authenticated-orcid":false,"given":"Leonel","family":"Varela Cagetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Moureau-Zabotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Zemmour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie","family":"Ferr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Giovaninni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Poizat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Lelong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"De Chaisemartin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5474-9146","authenticated-orcid":false,"given":"Emmanuel","family":"Mitry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite","family":"Tyran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Zioueche-Mottet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naji","family":"Salem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agn\u00e8s","family":"Tallet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.brachy.2023.03.004_bib0001","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","article-title":"Cancer statistics, 2008","volume":"58","author":"Jemal","year":"2008","journal-title":"Cancer J Clin"},{"key":"10.1016\/j.brachy.2023.03.004_bib0002","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1097\/CEJ.0000000000000163","article-title":"Trends of incidence and survival in squamous-cell carcinoma of the anal canal in France: a population-based study","volume":"25","author":"Bouvier","year":"2016","journal-title":"Eur J Cancer Prevent"},{"key":"10.1016\/j.brachy.2023.03.004_bib0003","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1470-2045(12)70080-3","article-title":"Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis","volume":"13","author":"Machalek","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.brachy.2023.03.004_bib0004","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF02604287","article-title":"Combined therapy for cancer of the anal canal","volume":"24","author":"Nigro","year":"1981","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.brachy.2023.03.004_bib0005","first-page":"4111","article-title":"Anal carcinoma: surgery does not influence prognosis when performed prior to concurrent radiochemotherapy","volume":"33","author":"Badakhshi","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.brachy.2023.03.004_bib0006","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ijrobp.2004.09.060","article-title":"Anal canal carcinoma: early-stage tumors< or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy","volume":"62","author":"Ortholan","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2023.03.004_bib0007","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal. A randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.brachy.2023.03.004_bib0008","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","article-title":"Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.brachy.2023.03.004_bib0009","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2023.03.004_bib0010","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2023.03.004_bib0011","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S1470-2045(13)70086-X","article-title":"Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2\u00d72 factorial trial","volume":"14","author":"James","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.brachy.2023.03.004_bib0012","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2023.03.004_bib0013","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomized UKCCCR Anal Cancer Trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.brachy.2023.03.004_bib0014","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.radonc.2013.05.037","article-title":"Faecal incontinence after chemoradiotherapy in anal cancer survivors: Long-term results of a national cohort","volume":"108","author":"Bentzen","year":"2013","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2023.03.004_bib0015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.radonc.2021.01.027","article-title":"Anorectal function and radiation dose to pelvic floor muscles after primary treatment for anal cancer","volume":"157","author":"Kronborg","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2023.03.004_bib0016","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/0360-3016(89)90521-X","article-title":"Interstitial curietherapy in the conservative treatment of anal and rectal cancers","volume":"17","author":"Papillon","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2023.03.004_bib0017","first-page":"505","volume":"23","author":"Gerbaulet","year":"2002"},{"key":"10.1016\/j.brachy.2023.03.004_bib0018","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.brachy.2016.07.007","article-title":"Low-dose-rate interstitial brachytherapy boost for the treatment of anal canal cancers","volume":"16","author":"Cordoba","year":"2017","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2023.03.004_bib0019","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.canrad.2014.08.001","article-title":"End of the commercialisation of 192Ir wires in France: Proposals of the groupe de Curieth\u00e9rapie de la SFRO","volume":"18","author":"Peiffert","year":"2014","journal-title":"Cancer\/Radioth\u00e9r"},{"key":"10.1016\/j.brachy.2023.03.004_bib0020","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.ejso.2014.07.030","article-title":"Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"40","author":"Glynne-Jones","year":"2014","journal-title":"EJSO"},{"key":"10.1016\/j.brachy.2023.03.004_bib0021","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3109\/02841867809127689","article-title":"The Paris system in interstitial radiation therapy","volume":"17","author":"Pierquin","year":"1978","journal-title":"Acta Radiol Oncol Radiat Phys Biol"},{"key":"10.1016\/j.brachy.2023.03.004_bib0022","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/0360-3016(95)00162-R","article-title":"Biologically effective dose distribution based on the linear quadratic model and its clinical relevance","volume":"33","author":"Lee","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2023.03.004_bib0023","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0360-3016(99)00330-2","article-title":"A simple method of obtaining equivalent doses for use in HDR brachytherapy","volume":"46","author":"Nag","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2023.03.004_bib0024","first-page":"205","article-title":"Dose escalation in chemoradiation for anal cancer: Preliminary results of RTOG 92-08","volume":"2","author":"John","year":"1996","journal-title":"Cancer J Sci Am."},{"key":"10.1016\/j.brachy.2023.03.004_bib0025","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1200\/JCO.2011.35.4837","article-title":"Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: Final analysis of the randomized UNICANCER ACCORD 03 Trial","volume":"30","author":"Peiffert","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.brachy.2023.03.004_bib0026","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.clon.2005.02.008","article-title":"Faecal incontinence: A late side-effect of pelvic radiotherapy","volume":"17","author":"Putta","year":"2005","journal-title":"Clin Oncol"},{"key":"10.1016\/j.brachy.2023.03.004_bib0027","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.ijrobp.2009.03.010","article-title":"Late side effects and quality of life after radiotherapy for rectal cancer","volume":"76","author":"Bruheim","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2023.03.004_bib0028","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/gut.44.1.77","article-title":"Prospective comparison of faecal incontinence grading systems","volume":"44","author":"Vaizey","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.brachy.2023.03.004_bib0029","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3109\/00365521.2014.983153","article-title":"Radiotherapy-induced mesorectum alterations: histological evaluation of 90 consecutive cases","volume":"50","author":"Bonetti","year":"2015","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.brachy.2023.03.004_bib0030","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.radonc.2018.04.012","article-title":"Abnormal neuronal response to rectal and anal stimuli in patients treated with primary radiotherapy for anal cancer","volume":"128","author":"Haas","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2023.03.004_bib0031","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0360-3016(01)01510-3","article-title":"The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy","volume":"50","author":"Weber","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2023.03.004_bib0032","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2023.03.004_bib0033","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.adro.2017.01.009","article-title":"Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dosepainted IMRT per RTOG 0529","volume":"2","author":"Mitra","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.brachy.2023.03.004_bib0034","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.ijrobp.2010.02.055","article-title":"High-dose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 study)","volume":"80","author":"Hannoun-Levi","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2023.03.004_bib0035","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0360-3016(93)90421-Q","article-title":"Chemoradiotherapy versus radiotherapy alone for anal cancer: a retrospective comparison","volume":"27","author":"Allal","year":"1993","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2023.03.004_bib0036","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0360-3016(96)00493-2","article-title":"Conservative treatment by irradiation of epidermoid cancers of the anal canal: Prognostic factors of tumoral control and complications","volume":"37","author":"Peiffert","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2023.03.004_bib0037","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/j.ijrobp.2005.05.047","article-title":"Prognostic value of tumor regression evaluated after first course of radiotherapy for anal canal cancer","volume":"63","author":"Chapet","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.brachy.2023.03.004_bib0038","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.canrad.2007.02.001","article-title":"Long-term results and prognostic factors of squamous cell carcinoma of the anal canal treated by irradiation","volume":"11","author":"Tournier-Rangeard","year":"2007","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.brachy.2023.03.004_bib0039","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.brachy.2019.08.005","article-title":"High-dose-rate vs. low-dose-rate interstitial brachytherapy boost for anal canal cancers","volume":"18","author":"Varela Cagetti","year":"2019","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2023.03.004_bib0040","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s00066-014-0628-y","article-title":"Role of brachytherapy in the treatment of cancers of the anal canal. Long-term follow-up and multivariate analysis of a large monocentric retrospective series","volume":"190","author":"Lestrade","year":"2014","journal-title":"Strahlenther Onkol"},{"key":"10.1016\/j.brachy.2023.03.004_bib0041","doi-asserted-by":"crossref","first-page":"21","DOI":"10.5114\/jcb.2019.82804","article-title":"Long-term results of chemoradiation plus pulseddose-rate brachytherapy boost in anal canal carcinoma: a mono-institutional retrospective analysis","volume":"11","author":"Arcelli","year":"2019","journal-title":"J Contemp Brachyther"},{"key":"10.1016\/j.brachy.2023.03.004_bib0042","doi-asserted-by":"crossref","first-page":"263","DOI":"10.5114\/jcb.2021.106247","article-title":"Pulse-dose-rate interstitial brachytherapy in anal squamous cell carcinoma: clinical outcomes and patients' health quality perception","volume":"13","author":"Bourdais","year":"2021","journal-title":"J Contemp Brachyther"},{"key":"10.1016\/j.brachy.2023.03.004_bib0043","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00464-004-2287-z","article-title":"Multimodal therapy of anal cancer added by new endosonographic guided brachytherapy","volume":"20","author":"Doniec","year":"2006","journal-title":"Surg Endosc"},{"key":"10.1016\/j.brachy.2023.03.004_bib0044","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.brachy.2007.02.152","article-title":"Clinical outcome after treatment with a brachytherapy boost versus external beam boost for anal carcinoma","volume":"6","author":"Oehler-J\u00e4nne","year":"2007","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2023.03.004_bib0045","doi-asserted-by":"crossref","first-page":"522","DOI":"10.5114\/jcb.2018.81025","article-title":"Efficacy and tolerance of high-dose-rate brachytherapy boost after external radiotherapy in the treatment of squamous cell carcinoma of the anal canal","volume":"10","author":"Bertin","year":"2018","journal-title":"J Contemp Brachyther"},{"key":"10.1016\/j.brachy.2023.03.004_bib0046","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.radonc.2022.03.019","article-title":"High dose rate brachytherapy in the management of anal cancer: A review","volume":"171","author":"Ali","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.brachy.2023.03.004_bib0047","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.brachy.2016.08.003","article-title":"Interstitial brachytherapy as a boost to patients with anal carcinoma and poor response to chemoradiation: Single-institution long-term results","volume":"15","author":"Gryc","year":"2016","journal-title":"Brachytherapy"},{"key":"10.1016\/j.brachy.2023.03.004_bib0048","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/j.ijrobp.2012.09.034","article-title":"Role of brachytherapy in the boost management of anal carcinoma with node involvement (CORS-03 study)","volume":"85","author":"Moureau-Zabotto","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"10.1016\/j.brachy.2023.03.004_bib0049","unstructured":"Isrctn.com. PLATO - Personalising anal cancer radiotherapy dose. Available at https:\/\/www.isrctn.com\/ISRCTN88455282."},{"key":"10.1016\/j.brachy.2023.03.004_bib0050","unstructured":"ClinicalTrials.gov. Lower-dose chemoradiation in treating patients with early-stage anal cancer, the DECREASE Study. 2021. Available at: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04166318."}],"container-title":["Brachytherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472123000314?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538472123000314?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T02:18:53Z","timestamp":1761531533000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538472123000314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1538472123000314"],"URL":"https:\/\/doi.org\/10.1016\/j.brachy.2023.03.004","relation":{},"ISSN":["1538-4721"],"issn-type":[{"value":"1538-4721","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of brachytherapy boost for anal canal cancers in the era of de-escalation treatments","name":"articletitle","label":"Article Title"},{"value":"Brachytherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.brachy.2023.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}